You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, April 2014
|
| DOI | 10.1007/s00432-014-1666-7 |
| Pubmed ID | |
| Authors |
Ulf Schnetzke, Peter Fix, Baerbel Spies-Weisshart, Karin Schrenk, Anita Glaser, Hans-Joerg Fricke, Paul La Rosée, Andreas Hochhaus, Sebastian Scholl |
| Abstract |
Approximately, 70 % of adult patients with de novo acute myeloid leukemia (AML) achieve a complete remission (CR) while 10-20 % of AML are refractory to induction chemotherapy. Furthermore, a significant proportion of AML patients in CR will relapse during or after consolidation treatment. There is no evidence for a standard salvage regimen and most centers use a combination of an anthracycline and cytarabine (AraC). The aim of this study was to investigate the impact of two age-adjusted regimens containing AraC and cyclophosphamide applied for the treatment of relapsed or refractory AML. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 22 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 21% |
| Researcher | 5 | 21% |
| Other | 4 | 17% |
| Student > Master | 4 | 17% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
| Agricultural and Biological Sciences | 3 | 13% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Engineering | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 4 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2014.
All research outputs
#21,162,249
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#2,053
of 2,632 outputs
Outputs of similar age
#196,024
of 228,431 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#27
of 29 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,431 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.